Don Sapatkin

University of Pittsburgh Medical School researchers walk us through multiple approaches they’ve tried in the past, are currently using or plan to use in the future, as well as the significant challenges ahead.

Previous research has found that immigrants have lower rates of heart disease, diabetes, dementia and other chronic health conditions compared with nonimmigrants. A new study adds kidney disease to the list.

This is the third approval for Fabhalta (iptacopan), which was discovered and developed by Novartis.

The Acute Dialysis and Pheresis Therapies (ADAPT) Program has grown from nine nurses to 12.

Patients with acute kidney injury requiring temporary hemodialysis often follow the protocol used for people on long-term dialysis, despite significant pathophysiological differences between the two.

A large study analyzed suicide deaths among veterans with newly diagnosed post-traumatic stress disorder (PTSD) who did or did not receive a course of evidence-based therapy.

Two groundbreaking studies shed light on combat’s lasting physical and psychological damage more than 50 years on.

The context matters — and it is not a matter of semantics.

Much of the association between trauma and suicide risk among university students can be explained by shame, a new study finds.

Researchers sought to determine whether mental health conditions affected women firefighters’ reproductive outcomes. They found a possible link between post-traumatic stress disorder (PTSD) and an indicator of reduced fertility.

There’s a dearth of research on older veterans with PTSD in long-term care settings. A new study sought to determine who they are.

A systematic review and network meta-analysis examined research on four types of treatment for children with post-traumatic stress disorder. Trauma-focused cognitive behavioral therapy was the clear winner.

In-depth interviews and an online survey found support for gene therapy as a treatment for inherited blood disorders, but also several obstacles that must be addressed.

Up to half of patients showed significant improvement in study results presented at the American Academy of Ophthalmology (AAO) annual meeting

One of two new studies found most patients doing well six years after treatment. Another study found blood cancers in 17% of patients given the therapy using a slightly different protocol.

The Phase I/II trials for rare forms of hereditary blindness further confirmed the potential for gene therapy treatments of congenital diseases of the retina.

“Cure” is not an immutable term, the authors of a new study write, and its meaning depends on the context in which it is used. Sometimes, it shouldn’t be.

The researchers took what they said was a conservative approach when plugging variables such as one-time and future costs into their updated model.

As supplemental screening for breast cancer becomes more common, the modeling study supplies long-term projections of how many deaths could be averted but also how many false-positive biopsy recommendations would be added.

CMS will provide key logistical support to states that participate in its outcomes-based funding model for gene therapy treatment for sickle cell disease.

Gene therapy is enormously complicated, inefficient and slow. Early tests of a newly developed machine learning model show how much faster, and more efficient, it might be.

The key to lowering gene therapy costs – and getting treatments to where they are most needed – could be making them in middle- low-income countries, argue the authors of a recent commentary in Nature.

The authors say their findings should not change women’s calculations about double, or bilateral mastectomy, which physicians generally discourage.

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, which accounted for nearly one-fifth of all pediatric hospitalizations in the U.S. before the pandemic.

The intent is for both parties to share information that will enhance the agency’s efficiency and quality of reviews.

Denmark has also set up a reimbursement arrangement for Hemgenix, which has a list price of $3.5 million in the U.S.

Gene therapies are incredibly expensive and tend to benefit small numbers of people, a combination that presents myriad financing challenges for patients, providers, payers and producers. A new study explored some of the options.

Monday’s action followed by one month the agency’s approval of another first — a monoclonal antibody immunization for newborns — against respiratory syncytial virus, the leading cause of infant hospitalizations in the United States

A new study has found that magnesium sulfate given between 30 weeks and 34 weeks’ gestation did not lower the incidence of cerebral palsy in premature infants.

The Centers for Disease Control and Prevention cleared the way for the first immunization approved to protect all young infants and at-risk older babies against respiratory syncytial virus (RSV). There are questions, though, about when insurance coverage will kick in.